printemailclick to share buttonfacebooktwitterlinkedin
Systemic Treatment Evidence-based Series (EBS), Evidence Summaries (ES) and Practice Guidelines (PG)

Systemic treatment includes drug treatment and new drugs that affect the whole body.

The Systemic Treatment guidance documents are produced by Expert Panels convened by Cancer Care Ontario. These panels work with the PEBC to gather and examine evidence on specific topics related to safe and effective systemic treatment for people with cancer in Ontario. The reports produced by these panels are available below.     

The PEBC has a formal and standardized process to ensure the currency of each document (please see the PEBC Assessment & Review Protocol for more information). This process guides clinical experts to assess a document’s current status and relevance. A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ) or the lead author of the document.


  • Regional Models of Care for Systemic Treatment: Standards for the Organization and Delivery of Systemic Treatment
    12-10 EBS: May 2007
    Status: CURRENT

Also see:

Evidence-based Series (EBS), Evidence Summaries (ES) and Guidelines (PG)

  • Systemic Therapy in Acute Lymphoblastic Leukemia
    12-16 ES: June 2016
    Status: CURRENT
  • The Use of Leucovorin in Colorectal Cancer
    12-17 ES: February 2016
    Status: CURRENT
  • Systemic Treatment of Acute Myeloid Leukemia (AML)
    Guideline 12-9: February 2016
    Status: CURRENT
  • Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy
    Guideline 12-15: November 2015
    Status: CURRENT

Safe Administration of Systemic Cancer Therapy

  • Safe Administration of Systemic Cancer Therapy Part 2: Administration of Chemotherapy and Management of Preventable Adverse Events
    12-12-2 EBS: March 2014
    Status: CURRENT
  • Safe Administration of Systemic Cancer Therapy: Introduction and General Methods
    12-12 EBS Methods: July 2012
    Status: CURRENT
  • Safe Administration of Systemic Cancer Therapy Part 1: Safety During Chemotherapy Ordering, Transcribing, Dispensing, and Patient Identification
    12-12-1 EBS: July 2012
    Status: CURRENT

Other Guidelines

  • Computerized Prescriber Order Entry (CPOE) in the Outpatient Oncology Setting
    12-14 ES: May 2012
    Status: CURRENT 
    This is one component of the Systemic Treatment Computerized Prescriber Order Entry (ST CPOE) Guideline . Also see the full ST CPOE Guidelines .
  • Radionuclide Therapy for Neuroendocrine Malignancies
    12-13 EBS: August 2011
    Status: CURRENT
  • Patient Safety Issues: Key Components of Chemotherapy Labelling
    12-11 PG: August 2009
    Status: CURRENT

For Education and Information Purposes

  • Liposomal Anthracyclines in the Management of Patients with HIV-positive Kaposi's Sarcoma
    12-8 PG
  • Use of Dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer
    12-5 PG
    The original guideline is available upon request at
  • The Role of Erythropoietin in the Management of Cancer Patients with Non-hematologic Malignancies Receiving Chemotherapy
    12-1 PG has been replaced by EBS #6-11 Treatment of Anemia with Erythropoietic Agents in Patients with Cancer - Adaptation/Adoption of ASH-ASCO Guidelines
    See: Hematology Evidence-Based Series 
  • Use of 5-HT3 Receptor-antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
  • The Role of Neurokinin-1 Receptor Antagonists in the Prevention of Emesis due to High-dose Cisplatin
  • The Role of Octreotide in the Management of Patients with Cancer
  • The Role of Colony-Stimulating Factor (CSF) in Patients Receiving Myelosuppressive Chemotherapy for the Treatment of Cancer
  • Use of Amifostine to Ameliorate the Toxic Effects of Chemotherapy in the Treatment of Cancer

McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Last modified: Wed, Jul 13, 2016
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?